Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $315
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Equal-Weight rating on Amgen and raises the price target from $300 to $315.
October 07, 2024 | 6:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Amgen and increased the price target from $300 to $315, indicating a positive outlook.
The increase in the price target from $300 to $315 by Barclays suggests a positive outlook for Amgen's stock, which could lead to a short-term price increase. The maintenance of an Equal-Weight rating indicates a balanced view, but the raised target price is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100